Aquestive Therapeutics, does not pass the ethical screen. The binding factor is interest/revenue 9.8%.
Aquestive Therapeutics, Inc.
AQST · Nasdaq · USD · Market cap $579M · 147 employees
Aquestive Therapeutics, Inc.
FAIL · Does not pass the screenPrice as of 13 Nov 2026Daily close, not a live quote
Screened 2026-11-13 · the tape above runs as of 08:09 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price3.91 USD at the 13 Nov 2026 close
- Fair valueUnder review: our model's value is 2.56x the price, above our 2.00x limit.
- Our regime readMarkdown, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans to puts (put/call 1.83)
- Last reviewed13 Nov 2026 (3 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: range not available (screen dated 2026-11-13).
- Trend Markdown
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 1.83, read 2026-11-14
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markdown label.
Aquestive Therapeutics, Inc. holds its Markdown at $3.91. Consolidating, no directional conviction, held for 107 days.
| Phase | Markdown · caution |
| Quantitative state | Consolidating, no directional conviction, held for 107 days |
| Price at the screen | $3.91 |
| Valuation | N/A trailing · -8.09 forward price to earnings |
| Values screen | FAIL · score 88.0 |
| Beta | 1.49 |
Five Screens, Shown in Full
Does not pass. Interest/revenue 9.8%
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 8.20% | Below 33% | Interest-bearing debt is just 8.2% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 23.38% | Below 33% | Cash held in interest-bearing accounts and securities is 23.4% of assets, under the one-third limit. | Pass |
| Receivables | 0.00% | Below 49% | Money owed to the company is 0.0% of assets, under the 49% limit. | Pass |
| Revenue purity | 9.80% | Below 5% | 9.8% of revenue comes from non-compliant sources, over the 5% line. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Aquestive Therapeutics, does not pass the ethical screen. The binding factor is interest/revenue 9.8%.
Read as at 2026-11-15. It updates when the underlying figures move, and past reads are kept below.
Aquestive Therapeutics, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 8%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
Follow this verdict
Get an email when AQST's ethical verdict changes
Today AQST does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Fair value under review. Our model's value is 2.56x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.
How a fair value is estimated: discounted cash flow (DCF).
The Street's RangeThird-party analyst targets. The average target sits +156% from the screen price.
Where our models see it going: no fair-value estimate yet, range not available, dated to the 2026-11-13 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words| Forward P/E | -8.1x |
| EPS, trailing | -0.66 |
| EPS, forward | -0.57 |
| Revenue growth | +38.1%strong top-line growth |
| Profit margin | -144.6%currently unprofitable |
| FCF yield | -4.65% |
| Current ratio | 7.19comfortably covers its short-term bills |
| Beta | 1.49moves a little more than the market |
| Short interest, float | 0.24% |
| 52-week range | 2.93 - 7.55 |
| Market cap | $579M |
| Employees | 147 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeAQST trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 9.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (9 analysts) rates it strong buy, with a mean price target of $9.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (9 analysts) rates it strong buy, with a mean price target of $9. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (9 analysts) rates it strong buy, with a mean price target of $9. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 8.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (9 analysts) rates it strong buy, with a mean price target of $9. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (9 analysts) rates it strong buy, with a mean price target of $9. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (9 analysts) rates it strong buy, with a mean price target of $9. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 4.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (9 analysts) rates it strong buy, with a mean price target of $9. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (9 analysts) rates it strong buy, with a mean price target of $9. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (9 analysts) rates it strong buy, with a mean price target of $9.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 15.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (9 analysts) rates it strong buy, with a mean price target of $9.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly Yahoo Finance · 29 Sep 2026
- Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film Yahoo Finance · 17 Sep 2026
- Aquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into Focus Insider Monkey · 8 Sep 2026
- Aquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into Focus Yahoo Finance · 8 Sep 2026
- Aquestive Therapeutics to Participate in Upcoming September Investor Conferences Yahoo Finance · 1 Sep 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-18 | ZALEWSKI THOMAS A. | Officer | 100,000 | · | |
| 2026-05-15 | BARBER DANIEL R | Chief Executive Officer | 8,257 | $35,413 | |
| 2026-03-10 | TOTH A ERNEST JR | Chief Financial Officer | 58,254 | $243,094 | |
| 2026-03-10 | BARBER DANIEL R | Chief Executive Officer | 180,677 | $753,965 | |
| 2026-03-10 | BOYD PETER E | Officer | 29,814 | $124,414 | |
| 2026-03-10 | BRAENDER LORI J | Officer | 40,102 | $167,346 | |
| 2026-03-10 | JUNG CASSIE | Chief Operating Officer | 45,791 | $191,086 | |
| 2026-03-10 | KORCZYNSKI SHERRY | Officer | 15,741 | $65,687 | |
| 2026-03-10 | CIOFFI MELINA | Officer | 25,311 | $105,623 | |
| 2026-03-09 | TOTH A ERNEST JR | Chief Financial Officer | 95,000 | · |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $4.34 | -8.4% | · | $916 | -8.4% |
| 2 months | $4.08 | -2.6% | · | $974 | -2.6% |
| 3 months | $4.03 | -1.4% | · | $986 | -1.4% |
| 6 months | $6.32 | -37.1% | · | $629 | -37.1% |
| 1 year | $3.58 | +11.0% | · | $1,110 | +11.0% |
| 2 years | $2.76 | +44.0% | · | $1,440 | +44.0% |
| 3 years | $2.12 | +87.5% | · | $1,875 | +87.5% |
| 5 years | $4.23 | -6.0% | · | $940 | -6.0% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever AQST does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.